Skip to main content
SpringerLink
Log in

Progression-free survival versus overall survival as the primary end point in anticancer drug trials: Increasingly relevant impact of therapy following progression

  • Current Reports/Oncology/Editor’s Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666–2676.

    Article  PubMed  CAS  Google Scholar 

  2. Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699–4707.

    Article  PubMed  CAS  Google Scholar 

  3. The ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099–2106.

    Article  Google Scholar 

  4. Gordon AN, Fleagle JT, Guthrie D, et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312–3322.

    PubMed  CAS  Google Scholar 

  5. Jassem J, Ramlau R, Santoro A, et al.: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698–1704.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77005, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: Increasingly relevant impact of therapy following progression. Curr Oncol Rep 11, 1–2 (2009). https://doi.org/10.1007/s11912-009-0001-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-009-0001-y

Keywords

Search

Navigation